# ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2008

WEDNESDAT

\*AC5V66WU\*

A32 28/01/2009 COMPANIES HOUSE 228

#### ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2008

#### **CONTENTS**

#### **PAGE**

- 1 Report of the Directors
- 3 Statement of directors' responsibilities
- 4 Report of the independent auditors
- 6 Profit and loss account
- 7 Statement of total recognised gains and losses and reconciliation of movement in shareholders' funds
- 8 Balance sheet
- 9 Notes forming part of the financial statements

#### **DIRECTORS**

H Solomon (USA)

R Stafford (Republic of Ireland)

D Burke (Republic of Ireland)

#### SECRETARY AND REGISTERED OFFICE

A Livingstone

Bourne Road

Bexley

Kent DA5 1NX

#### **COMPANY NUMBER**

532832

#### **AUDITORS**

**BDO Stoy Hayward LLP** 

2 City Place, Beehive Ring Road

Gatwick

RH6 0PA

#### REPORT OF THE DIRECTORS FOR THE YEAR ENDED 31ST MARCH 2008

The directors submit their report together with the audited financial statements for the year ended 31st March 2008.

#### **Principal Activity**

The principal activities of the Company are the manufacture and distribution of ethical and over-the-counter pharmaceutical products. The Company also engages in the purchase and sale of product licences.

#### Results & Dividends

The profit and loss statement is set out on page 6 and shows the Company's results for the year, together with the retained profits.

No dividend was paid or proposed.

#### **Business Review**

Trading for the year was in line with expectations.

The Company has continued to invest in the project to develop a new delivery method for one of our products. Expenditure on this project is nearing completion as we anticipate applying for regulatory approval within the next few months. We received a payment during the year for licencing certain rights to this product and future receipts are dependent upon further milestones being met.

Key performance indicators compared to previous years are as follows:

	<u>2008</u>	<u>2007</u>
	(000 <u>3)</u>	(£000)
Turnover	25,338	25,660
Gross Profit	7,841	8,695
Operating Loss	(431)	(2,373)
Interest Received	284	286

The Company continues to operate within a difficult trading environment. The government has taken the opportunity to review the PPRS at its mid-term stage and the replacement scheme is unlikely to be any more favourable to the company than the previous scheme.

During the year ended 31st March 2008 the company announced it would close its operational facility resulting in redundancy for a significant number of employees along with other associated reorganisation costs. All manufacturing is now outsourced and the company is planning to relocate to more suitable premises in early 2009. As a result of these changes, the directors are confident that the long term profitability of the company will be secured.

During the year the Company sold the rights to some of its older products and continues to review its product portfolio in light of current market pressures.

# REPORT OF THE DIRECTORS FOR THE YEAR ENDED 31ST MARCH 2008 (continued)

The Directors consider the Balance Sheet position is still strong despite the investment in Research and Development.

Working capital remains healthy and we do not anticipate the need for additional funding.

#### Research & Development

Research & Development is primarily focused on maintaining our current marketing authorisations. Over the last few years, however, we have been working on a project to develop a new delivery method for one of our products which we believe will, amongst other benefits, greatly enhance the patients' quality of life.

#### Risks and Uncertainties

The main financial risks arising from the company's activities are credit risk, interest rate risk, liquidity risk and foreign currency risk. These are monitored by the board of directors and were not considered to be significant at the balance sheet date.

#### Directors

The directors of the Company during the year ended 31st March 2008 were:-

H Solomon (USA)

R Stafford (Republic of Ireland)

D Burke (Republic of Ireland)

None of the directors had any interest in the share capital of the Company during the year or previous year.

Mr R Stafford retires by rotation and, being eligible, offers himself for re-election.

The interests of the directors in the shares of the ultimate parent company are disclosed in the accounts of that company.

#### Auditors

All of the current directors have taken all the steps that they ought to have taken to make themselves aware of any information needed by the company's auditors for the purposes of their audit and to establish that the auditors are aware of that information. The directors are not aware of any relevant audit information of which the auditors are unaware.

A resolution to reappoint BDO Stoy Hayward LLP as auditors will be proposed at the next annual general meeting.

By order of the board

A Livingstone

Secretary

TH January 2009

-2-

# STATEMENT OF DIRECTORS' RESPONSIBILITIES FOR THE YEAR ENDED 31ST MARCH 2008

#### Directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

United Kingdom Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### REPORT OF THE INDEPENDENT AUDITORS

#### To the shareholders of Forest Laboratories UK Limited

We have audited the financial statements of Forest Laboratories UK Limited for the year ended 31 March 2008 which comprise the profit and loss account, the statement of total recognised gains and losses, the reconciliation of movements in shareholders' funds, the balance sheet and the related notes. These financial statements have been prepared under the accounting policies set out therein.

#### Respective responsibilities of directors and auditors

The directors' responsibilities for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the statement of directors' responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and have been properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the directors' report is not consistent with those financial statements, if the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed.

We read the directors' report and consider the implications for our report if we become aware of any apparent misstatements within it.

Our report has been prepared pursuant to the requirements of the Companies Act 1985 and for no other purpose. No person is entitled to rely on this report unless such a person is a person entitled to rely upon this report by virtue of and for the purpose of the Companies Act 1985 or has been expressly authorised to do so by our prior written consent. Save as above, we do not accept responsibility for this report to any other person or for any other purpose and we hereby expressly disclaim any and all such liability.

#### Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the company's circumstances, consistently applied and adequately disclosed.

# REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF FOREST LABORATORIES UK LIMITED (Continued)

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

#### Opinion

#### In our opinion:

- the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the company's affairs as at 31 March 2008 and of its loss for the year then ended; and
- the financial statements have been properly prepared in accordance with the Companies Act 1985.

• the information given in the Directors' Report is consistent with the financial statements.

BDO STOY HAYWARD LLP

Chartered Accountants and Registered Auditors

Gatwick

Date 21 Juney 2009.

FOREST LABORATORIES UK LIMITED

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2008

	NOTE	-	2008		<u>2007</u>
TURNOVER	2		25,337,956		25,659,881
Cost of Sales		-	17,497,081	-	16,964,952
GROSS PROFIT			7,840,875		8,694,929
Distribution Costs		5,005,022		4,933,873	
Administrative Expenses		5,718,726	· <u>-</u>	6,459,178	
			(10,723,748)		(11,393,051)
Other operating income			2,451,695		325,000
OPERATING LOSS	3		(431,178)		(2,373,122)
Interest Receivable	6		283,907		286,008
Pension finance charges	7		(69,000)		(53,000)
LOSS ON ORDINARY ACTIVITIES BEFORE TAXATIO	)N		(216,271)		(2,140,114)
Taxation	8		33,000		(147,600)
LOSS FOR THE YEAR	18		(183,271)		(2,287,714)

All amounts relate to continuing activities.

The notes on pages 9 to 22 form part of these financial statements.

# STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES FOR THE YEAR ENDED 31ST MARCH 2008

	2008	<u>2007</u>
STATEMENT OF TOTAL RECOGNISED GAINS AN	D LOSSES	
Loss for the financial year	(183,271)	(2,287,714)
Actual return less expected return on pension scheme assets	(1,669,000)	103,000
Experience losses arising on scheme liabilities	(18,000)	(1,496,000)
Change in assumptions underlying the present value of scheme liabilities	1,819,000	88,000
Share based payments	55,896	80,361
TOTAL RECOGNISED GAINS AND LOSSES IN THE YEAR	4,625	(3,512,353)
RECONCILIATION OF MOVEMENTS IN SHAREHO	OLDERS' FUNDS	
Loss for the financial year	(183,271)	(2,287,714)
Actuarial gain / (loss) on pension scheme	132,000	(1,305,000)
Share based payments	55,896	80,361
NET INCREASE/(DECREASE) IN SHAREHOLDERS' FUNDS	4,625	(3,512,353)
Opening shareholders' funds	1,626,358	5,138,711
CLOSING SHAREHOLDERS' FUNDS	1,630,983	1,626,358

The notes on pages 9 to 22 form part of these financial statements.

#### **BALANCE SHEET AT 31ST MARCH 2008**

	NOT	<u> </u>	2008		2007 £
FIXED ASSETS			£		<u> </u>
Tangible assets	9		1,094,350		1,719,495
Intangible assets	10		3,076,267		3,472,625
Investments	11		100		100
Myosunones			4,170,717		5,192,220
CURRENT ASSETS					
Stocks	12	3,448,371		4,190,255	
Debtors	13	5,444,961		5,147,325	
Cash at bank		5,298,441_		3,276,637	
		14,191,773		12,614,217	
CREDITORS - amounts falling					
due within one year	14	12,888,507		11,691,079	
NET CURRENT ASSETS			1,303,266		923,138
TOTAL ASSETS less CURRENT					
LIABILITIES			5,473,983		6,115,358
PROVISIONS FOR LIABILITIES					
AND CHARGES					
Deferred taxation	15		(60,000)		(93,000)
Pension liability	16		(3,783,000)		(4,396,000)
			1,630,983		1,626,358
CAPITAL and RESERVES					
Called up Share Capital	17		534,938		534,938
RESERVES					
Capital reserve	18	564,662		564,662	
Profit and loss account	18	531,383		526,758	
1 Tone and 1033 account			1,096,045		1,091,420
			1,630,983		1,626,358

Approved and authorised for issue by the Board of Directors

R. Stafford ( Haday

Date: 2009

The notes on pages 9 to 22 form part of these financial statements.

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

#### 1. Accounting Policies

#### Convention

These financial statements have been prepared under the historical cost convention and are in accordance with applicable accounting standards. The principal accounting policies which the directors have adopted consistently within that convention are set out below.

#### Foreign Currency

Foreign currency transactions are translated at the rates ruling when they occurred. Assets and liabilities in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Exchange profits and losses are included in the Company's trading results.

#### Turnover

Turnover is the amount derived from the provision of goods and services falling within the Company's ordinary activities after deduction of trade discounts and value added tax. Turnover is recognised when the risks and rewards of owning the goods has passed to the customer, which is generally on delivery.

#### Research & Development

Research and development expenditure is written off in the year in which it is incurred.

#### Deferred Taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed by the balance sheet date except for:

- deferred tax is not recognised on timing differences arising on revalued properties unless the company has entered into a binding sale agreement and is not proposing to take advantage of rollover relief; and
- the recognition of deferred tax assets is limited to the extent that the company is anticipated to make sufficient taxable profits in the future to absorb the reversal of the underlying timing differences.

Deferred tax balances are not discounted.

#### Share-based payment

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to the income statement over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. There are no market based vesting conditions.

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

#### Accounting Policies (continued)

#### Tangible Fixed Assets and Depreciation

For all tangible fixed assets, with the exception of freehold land, depreciation is calculated to write down their cost or valuation to their estimated residual values by equal annual instalments over the period of their estimated useful economic lives, which are considered to be:

Freehold Buildings
Plant and machinery fixtures a

40 years

Plant and machinery, fixtures and fittings

Up to 10 years

Motor vehicles

Up to 4 years

#### Intangible fixed assets and amortisation

Intangible assets consist of trademarks which are recorded at cost less accumulated amortisation. Amortisation is provided on a straight-line basis over the directors estimate of the useful economic life of 10 years.

#### Patents, Licences and Trade Marks

The normal expenses of maintaining patents, licences and trade marks are charged against the Company's trading results as incurred.

#### Stock and Work in Progress

Stock and work in progress are valued at the lower of cost and net realisable value.

Cost is calculated as follows:-

Raw materials, bought in parts and consumable stores

cost of purchase on first in, first out basis

Work in progress and

finished goods

cost of raw materials and labour together with attributed overheads based on the

normal level of activity.

#### Pension Costs

The group operates a defined benefit scheme and FRS 17 "Retirement Benefits" has been adopted in full during the year to 31 March 2008. Under FRS 17 pension scheme assets are measured at fair value and scheme liabilities are valued using a projected unit method, discounted at the current rate of return on high quality corporate bonds. The full service cost of benefits accruing during the year is charged against operating profit. The expected return on scheme assets and the change in the net present value of scheme liabilities are included in other finance charges. Actuarial gains and losses are recognised in the statement of total recognised gains and losses. The scheme deficit is recognised in full in the balance sheet.

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

#### 1 Accounting Policies (continued)

Pension Costs (cont'd)

Changes in the defined benefit pension scheme asset or liability arising from factors other than cash contribution by the company are charged to the profit and loss account or the statement of total recognised gains and losses in accordance with FRS17 'Retirement benefits'.

#### Leased assets

All leases are treated as operating leases. Their annual rentals are charged to the profit and loss account on a straight line basis over the term of the lease.

#### 2. Analysis of Turnover

Turnover is attributable mainly to the manufacture and distribution of Ethical and Over The Counter (OTC) Pharmaceuticals.

Turnover attributable to each of the Company's geographical markets is:-

	<u>2008</u>	<u>2007</u>
	<u>£</u>	$oldsymbol{ar{ t t}}$
United Kingdom	21,480,538	21,680,489
Republic of Ireland	1,011,332	961,656
Rest of Europe	1,449,398	1,082,369
Middle East	582,183	526,545
Asia	105,932	414,944
Africa	61,636	27,155
Canada	24,456	372,296
Central and South America	318,809	300,182
Australia and New Zealand	303,672	294,245_
Australia and New Zealand	25,337,956	25,659,881
	<del></del>	<del></del>

All assets of the company are situated within the United Kingdom, and all trading results are generated from operations within the United Kingdom.

3.	Operating (Loss)	2008	2007
	Operating (loss) is arrived at	$\underline{\mathbf{f}}$	<u> </u>
	after charging / (crediting):		
	Depreciation	284,235	199,739
	Amortisation	496,358	491,360
	Impairment loss on plant and machinery	314,774	-
	Profit on sale of product rights	(2,451,695)	(325,000
	Research and Development Expenditure	1,967,963	
	Restructuring costs	1,766,559	-
	(Profit) / Loss on foreign currency transactions	(57,070)	8,899
	Auditor's remuneration		
	- audit services	43,700	48,940
	- non audit services	3,360	19,530
	Operating leases - plant and machinery	12,060	12,618
	Operating leases - motor vehicles	64,035	44,773
	Share-based payment	55,896	80,361
4.	Employees		
	The average monthly number of employees within e		
		<u>2008</u>	<u>200</u>
		<u>No</u>	<u>V</u>
	Production	60	•
	Distribution	39	4
	Administrative	28	
		127	13
	The costs incurred in respect of these employees we		
		<u>2008</u>	<u> 200</u>
		$\underline{\mathfrak{L}}$	
	Wages and salaries	3,822,788	3,752,06
	Social security costs	450,745	454,11
	Other pension costs	855,359	330,00
		5,128,892	4,536,17
_	Directors' Emoluments		
5.		<u>2008</u>	<u>20</u>
5.		^	
5.		£	
5.	Aggregate emoluments	± 	33,1

6.	Interest Receivable		
0.	micrest receivable	<u>2008</u>	<u>2007</u>
			<u>£</u>
	Bank interest	283,907	286,008
-	D. C.	2008	<u>2007</u>
7.	Pension finance charges	<u>2008</u> £	2001
			527 000
	Expected return on pension scheme assets	645,000 (714,000)	527,000 (580,000)
	Interest on pension scheme liabilities	(714,000)	<u> </u>
	=	(69,000)	(53,000)
8.	Tax on loss on ordinary activities		
		2008	<u>2007</u>
		<u> </u>	<u>£</u>
	Analysis of tax charge:		
	UK corporation tax Current Year	-	138,000
	Deferred tax (note 15)	(33,000)	9,600
		(22,000)	147,600
	Tax charge on loss on ordinary activities	(33,000)	=======================================
	Factors affecting the UK tax charge for the year:	<u>2008</u>	<u>2007</u>
	,	$\overline{\mathfrak{t}}$	£
	Les andinome activities before tay	216,271	2,140,114
	Loss on ordinary activities before tax  Loss on ordinary activities at the standard	2.0,=,.	, ,
	rate of UK corporation tax at 30% (2006 – 30%)	(64,881)	(642,034)
	Effects of:		10.000
	Expenses not deductible for tax purposes	13,647	18,000
	Capital allowances in (excess of depreciation)/	41,475	(507)
	less than depreciation Share option exercise tax deduction	-	(43,868)
	Research & Development tax credit	(23,700)	(45,000)
	FRS 17 adjustments not allowable for tax	39,600	(191,100)
	Other timing differences	76,500	(34,800)
	Underprovision in prior years	(01 (41)	138,000 939,309
	Tax losses (utilised)/not credited to Profit and Loss accoun-	t (82,641)	
	Current tax charge for the year		138,000

9. Tangible Asso	FREEHOLD LAND &	FURNITURE FIXTURES &	PLANT & MACHINERY	MOTOR VEHICLES	TOTAL
	BUILDINGS £	FITTINGS £	<u>£</u>		<u>£</u>
Cost at 1st April 2007	1,758,735	621,061	3,344,941	25,264	5,750,001
Additions during year Disposals Impairment loss	-	16,037	7,312 (176,856) (2,355,194)	-	23,349 (176,856) (2,355,194)
Cost at 31st March 2008	1,758,735	637,098	820,203	25,264	3,241,300
Depreciation at 1st April 2007	820,636	514,839	2,687,383	7,648	4,030,506
Charge for the year On disposals Impairment loss	35,219 -	54,066 -	190,990 (127,371) (2,040,420)	3,960 -	284,235 (127,371) (2,040,420)
Depreciation at 31st March 2008	855,855	568,905	710,582	11,608	2,146,950
Net book value at 31st March 2008	902,880	68,193	109,621	13,656	1,094,350
Net book value at 31st March 2007	938,099	106,222	657,558	17,616	1,719,495
10. <u>Intangible A</u>	<u>ssets</u>			Trade Marks	
			<u>2008</u> <u>£</u>		2007 <u>£</u>
Cost At 1st April			5,013,656		5,013,656
Additions			100,000		-
At 31st March			5,113,656		5,013,656
Amortisation At 1st April			1,541,031		1,049,671
provided for in year			496,358		491,360
at 31st March			2,037,389		1,541,031
Net book value at 31st March			3,076,267		3,472,625

# NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

#### 11. Fixed Asset Investments

# Subsidiaries and Related Companies

The following companies were incorporated in the UK and were dormant at 31st March 2008.

	Unquoted shares $\frac{\text{at cost}}{\underline{\mathbf{f}}}$
Subsidiary Pharmax Limited	100
Cost at 31st March 2007 and 31st March 2008	<u>100</u>

The Company has taken advantage of the exemption granted under S228 (1) of the Companies Act 1985 from preparing consolidated financial statements being itself a wholly owned subsidiary undertaking.

12.	Stocks	<u>2008</u> <u>£</u>	<u>2007</u> <u>£</u>
	Raw materials	1,219,752	1,435,268
	Work in progress	391,348	297,041
	Finished goods and goods for resale	1,837,271	2,457,946
		3,448,371	4,190,255

13.	<u>Debtors</u>		
		2008	<u>2007</u>
		£	$oldsymbol{ar{\mathbf{t}}}$
	Trade debtors	5,252,330	5,053,832
	Prepayments and accrued income	192,631	
	Corporation Tax	-	47,399
		5,444,961	5,101,231
14.	All debts fall due for payment within one year.  Creditors - Amounts falling due within one year		
		2008 <u>£</u>	2007 £
	Trade creditors	709,841	1,533,105
	Amounts owed to Group undertakings	9,298,130	8,764,789
	Other creditors	262,822	265,358
	Accruals and deferred income	2,288,327	962,452
	Other Taxation and Social Security	329,387	165,375
		12,888,507	11,691,079

# FOREST LABORATORIES UK LIMITED NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

15.	Provisions for Liabilities and Charges Deferred Taxation		
	Deterred Taxation	<u>2008</u>	2007
	Provision for deferrred tax	<u>r</u>	<b>±</b>
	Accelerated capital allowances at 1st April	(93,000)	(83,400)
	Transfer to profit and loss account (note 8)	33,000	(9,600)
	Provision at 31st March	(60,000)	(93,000)

#### 16. Pension Scheme

The Company operates a defined benefit pension scheme for the majority of its employees who joined the scheme prior to 6th April 1993. Any new entrants to the Company's pension scheme, subsequent to 6th April 1993, joined a money purchase scheme. The assets of the scheme are held in a separate trustee administered fund.

The pension cost relating to this scheme is assessed every three years in accordance with the advice of a qualified actuary using the projected unit method. The most recent formal valuation, at 30th June 2006, indicated that, on the basis of service to date and current salaries, the scheme's assets were sufficient to meet 55% of its liabilities. It was assumed that the investment returns would be 6.6% per annum, that salary increases would average 4.5% per annum and that present and future pensions would increase at the rate of inflation up to a maximum of 5% per annum.

At 31st March 2008 the scheme, which is contracted out of the state scheme, had assets of approximately £8.5m (2007 - £8.7m). Contibutions to the scheme by employees and the company have been maintained in accordance with the recommendations of the actuary in his previous valuation. The company has recently reviewed the funding rate in light of the results of the valuation and is committed to pay 16.4% of total pensionable salaries each year until the next valuation. Additionally, the company will pay a minimum of £87,600 per month from January 2008 for ten years in order to reduce the deficit in the scheme.

A full actuarial valuation of the mixed benefits scheme was carried out at 30th June 2006 and updated at 31st March 2008 by a qualified independent actuary on a FRS 17 basis. The major assumptions used by the actuary were:

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Inflation Assumption	3.7%	3.1%	2.9%
Rate of increase in salaries	3.8%	3.2%	3.0%
Rate of increase of pensions in payment	3.6%	3.0%	2.7%
Rate of increase for deferred pensioners	3.7%	3.1%	2.9%
Discount Rate	6.9%	5.4%	4.8%

# NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

# 16. Pension Scheme (Continued)

The assets in the scheme and the expected rate of return at 31st March 2008 were:

	Long-		Long-		Long-	
	term rate of return	Value at	term rate of return	Value at	term rate of return	Value at
	expected at 2008	2008 <u>£</u>	expected at 2007	2007 <u>£</u>	expected at 2006	2006
Equities	7.5%	6,176,000	7.8%	6,432,000	7.0%	7,000,000
Bonds	4.5%	941,000	4.8%	948,000	4.5%	1,800,000
Cash	5.3%	1,416,000	5.3%	1,285,000		600,000
Rebates Du	ıe	-		-		100,000
Total mark of assets	et value	8,533,000	-	8,665,000	•	9,500,000
Present val		(12,316,000)	)	(13,061,000)		(13,100,000)
Deficit in t	he scheme	(3,783,000)	<u>,                                    </u>	(4,396,000)		(3,600,000)
Related det	ferred	1,059,240		1,318,800		1,080,000
Net pensio on a FRS 1		(2,723,760	<u> </u>	(3,077,200)		(2,520,000)

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

16. Pension Scheme (continued)			
Analysis of amounts charged to operating profit for the pension	scheme		
	<u>2008</u>		<u>2007</u>
Current service cost	342,000		330,000
- -	342,000	=	330,000
Analysis of amount charged to interest payable for the pension s	cheme		
Expected return on the pension scheme assets	645,000		527,000
Interest on pension scheme liabilities	(714,000)		(580,000)
Net loss charged to other finance charges	(69,000)	=	(53,000)
Analysis of amounts recognised in the Statement of Total Recognised Gains and Losses (STRGL)			
Actual return less expected return on net assets	(1,669,000)		103,000
Experience losses arising on scheme liabilities	(18,000)		(1,496,000)
Changes in assumptions underlying the present value of scheme liabilities	1,819,000		88,000
Net actuarial gain / (loss) recognised	132,000	=	(1,305,000)
History of experience (losses) / gains	2008	2007	<u>2006</u>
Actual return less expected return on pension	(1.660.000)	103,000	1,000,000
scheme assets - As % of year end pension scheme assets	(1,669,000) (19.5%)	1.2%	1,000,000
Experience losses arising on the scheme liabilities	(18,000)	(1,496,000)	(900,000)
-As % of present value of year end scheme liabilities	(0.1%)	(11.5%)	(6.9%)
Changes in assumptions underlying the present	1,819,000	88,000	(700,000)
value of the scheme liabilities -As % of present value of year end scheme liabilities	14.8%	0.7%	(5.4%)
Actuarial gain / (loss) recognised in the statement of recognised gains and losses	132,000	(1,305,000)	(600,000)
- As % of present value of year end scheme liabilities	1.1%	(10.0%)	(4.6%)

The experience gains and losses are those resulting from the actual performance of the scheme being different from that predicted, for example from changes in economic conditions, from performance of the investment managers who manage the scheme's assets or from changes in the demographic profile of the scheme members.

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

16.	Pension Scheme (continued)		
	Movements in deficit during the year	<u>2008</u>	<u>2007</u>
	Deficit in scheme at beginning of year	r (4,396,000)	(3,600,000)
	Current service cost	(342,000)	(330,000)
	Contributions paid	892,000	892,000
	Other finance costs	(69,000)	(53,000)
	Actuarial gain / (loss)	132,000	(1,305,000)
	Deficit in the scheme at end of year	(3,783,000)	(4,396,000)
17.	Share Capital	2008 £	<u>2007</u> <u>£</u>
	<u>Equity</u>	_	
	Authorised, issued and fully paid		
	2,150 Ordinary shares of 10p each	215	215
	21,500 Deferred shares of 10p each	2,150	2,150
	12% non-cumulative redeemable preference shares of £1 each	532,573	532,573
	•	534,938	534,938

Ordinary shareholders have 1,000 votes per share and the right to all profits after payment of the preference dividend. On a winding up, following payment to the Preference Shareholders, Ordinary Shareholders will receive £100 per share and the balance of any assets following payment to Deferred Shareholders.

Deferred Shareholders have one vote per share, no rights to share in the profits, and on a winding up, repayment of the amount paid up following payment to the preference shareholders and £100 per Ordinary Share.

Preference Shareholders have one vote per share and in a winding up, surplus assets remaining after payment of liabilities shall first be applied to repaying the paid up amount on their shares. The shares were issued on 26th May 1978 and can be redeemed only at the Company's option. The Company must give three months written notice of redemption. The shares would be redeemed at par value.

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

18.	Reserves	Non-distributable reserve	Profit and loss account
	Balance at 1st April 2007	564,662	526,758
	Loss for the financial year	-	(183,271)
	Share based payment	-	55,896
	Other net recognised gains and losses	<u> </u>	132,000
	Balance at 31st March 2008	564,662	531,383

#### 19. Share-based payment

The group adopted FRS 20 'Share-based Payment during the year ended 31st March 2007. Prior to this no amounts were reflected in respect of share-based payments.

For 2008, the impact of share-based payments is a net charge to income of £55,896 (2007 £80,361). The expense has been included in the administrative expenses line of the income statement. There was no impact on Net Assets.

Senior managers and certain other members of staff participate in an equity settled share option scheme operated by the parent company, Forest Laboratories Inc whose shares are listed on the New York Stock Exchange. The options vest over a 6 year period (2007: 5) from the date of grant and will lapse if not exercised within six years from the date of grant. In addition, the options will lapse 3 months after an individual leaves the company's employment. There are no market-based vesting conditions.

The following assumptions were used in determining the fair values of stock options using the Black-Scholes model:

	<u>2008</u>	<u>2007</u>
Expected dividend yield	0%	0%
Expected stock price volatility	35.15%	29.63%
Risk-free interest rate	4.20%	4.80%
Expected life of options (years)	6	5
	2008	2007
The share-based remuneration expense (note 3) c	omprises:	
Equity-settled schemes	55,896	80,361

#### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2008

#### 20. Commitments under operating leases

The Company's annual commitments under non cancellable operating leases is as follows:-

	<u>2008</u>	<u>2007</u>
	$\underline{\mathbf{t}}$	<u>£</u>
Plant and machinery - expiring between 2 and 5 years	5,636	12,060
	5,636	12,060

#### 21. Related party transactions

The Company has taken advantage of the exemption allowed by FRS8 Related Party Transactions not to disclose any transactions or balances with entities which have 90% or more voting rights controlled within the Group.

During the year the Company traded with a distributor in Ireland, Ocean Healthcare Ltd, 50% of whose shares were owned by a member of the close familty of one of the Company's directors. The transactions have been carried out at arm's length.

	<u>2008</u>	<u>2007</u>
Sales during the year  Due from Ocean Healthcare at 31st March  Provision for doubtful debts	332,772 217,905 11,387	359,933 256,456 

#### 22. Cash Flow Statement

The Company has taken advantage of the exemption allowed under Financial Reporting Standard 1 "Cash Flow Statements" not to produce a cash flow statement, as it is a wholly owned subsidiary of Pharmax Holding Limited. A Group cash flow statement is included in the financial statements of Pharmax Holding Limited, the United Kingdom parent company. Copies of the consolidated financial statements of Pharmax Holding Limited are available from Companies House.

#### 23 Parent Company

The Company's ultimate parent company is Forest Laboratories Inc., a company incorporated in the USA.